147 related articles for article (PubMed ID: 32560964)
1. Facts, not Fear: Safety of Hydroxychloroquine.
Kuraitis D; Murina A
Am J Med Sci; 2020 Aug; 360(2):199-200. PubMed ID: 32560964
[No Abstract] [Full Text] [Related]
2. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J; Deniau B; Battistella M; de Masson A; Bensaid B; Jachiet M; Lazaridou I; Bagot M; Bouaziz JD;
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2777-2779.e1. PubMed ID: 32525093
[No Abstract] [Full Text] [Related]
3. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Schwartz RA; Janniger CK
Dermatol Ther; 2020 May; 33(3):e13380. PubMed ID: 32253799
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF
Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372
[No Abstract] [Full Text] [Related]
5. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Litaiem N; Hajlaoui K; Karray M; Slouma M; Zeglaoui F
Dermatol Ther; 2020 Jul; 33(4):e13565. PubMed ID: 32401410
[No Abstract] [Full Text] [Related]
6. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
7. Erythema multiforme in the context of SARS-Coronavirus-2 infection.
Sánchez-Velázquez A; Falkenhain D; Rivera Díaz R
Med Clin (Barc); 2020 Aug; 155(3):141. PubMed ID: 32475615
[No Abstract] [Full Text] [Related]
8. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
Paliani U; Cardona A
Eur J Intern Med; 2020 Aug; 78():1-3. PubMed ID: 32553587
[No Abstract] [Full Text] [Related]
9. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].
Tomcsányi J; Tomcsányi K
Orv Hetil; 2020 Apr; 161(17):689-691. PubMed ID: 32324363
[TBL] [Abstract][Full Text] [Related]
10. Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.
Kang Y; Wang H; Chen H; Wang B; Yang Y; Zhao X; Ran Q; Wei J
Int Heart J; 2020 Sep; 61(5):1056-1058. PubMed ID: 32921678
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
Marmor MF
Am J Ophthalmol; 2020 Aug; 216():A1-A2. PubMed ID: 32439074
[No Abstract] [Full Text] [Related]
12. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Habibzadeh P; Moghadami M; Lankarani KB
Med Hypotheses; 2020 Oct; 143():109847. PubMed ID: 32460209
[No Abstract] [Full Text] [Related]
13. [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?].
Defoort-Dhellemmes S
J Fr Ophtalmol; 2020 Jun; 43(6):548-549. PubMed ID: 32451138
[No Abstract] [Full Text] [Related]
14. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
Romano MR; Raimondi R; Montericcio A; Allegrini D
Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2871. PubMed ID: 32385749
[No Abstract] [Full Text] [Related]
15. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19).
Robustelli Test E; Vezzoli P; Carugno A; Raponi F; Gianatti A; Rongioletti F; Sena P
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e457-e459. PubMed ID: 32386448
[No Abstract] [Full Text] [Related]
16. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Yahya AS; Khawaja S; Chukwuma J
Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32441496
[No Abstract] [Full Text] [Related]
17. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Roden DM; Harrington RA; Poppas A; Russo AM
Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
[No Abstract] [Full Text] [Related]
18. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
19. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].
Zaidel EJ; Wyss Quintana FS; Sosa Liprandi Á; Mendoza I; Márquez MF; Nuñez E; Barbosa M; Baranchuk A
Medicina (B Aires); 2020; 80(3):271-274. PubMed ID: 32442941
[TBL] [Abstract][Full Text] [Related]
20. How to manage rheumatic patients during the coronavirus pandemic.
Parisi S; Ditto MC; Finucci A; Fusaro E
Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
